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reason for the high disease burden is that the vaccine has not 
yet been adopted and implemented by all countries, especially 
developing countries. 
Several studies2 have shown that introducing Hib vaccines in 
developing countries can result in a reduction of invasive Hib 
disease rates by over 80%.
The Hib vaccine has undergone several developments over 
the years. Initially an Hib polysaccharide (PRP) vacccine was 
developed. However, the immunological response to this 
vaccine was age dependent (as with other polysaccharide 
vaccines) with a poor response among those aged less 
than 2 years. Further development was undertaken; the 
Hib polysaccharide was conjugated to a carrier protein 
and this process then gave an effective vaccine that could 
be administered to the under 2-year age group. This has 
allowed many countries to include Hib vaccine in their 
national Expanded Program on Immunization (EPI). Despite 
this improvement, Hib vaccines are not affordable to many 
countries that need them most.
In order to minimise the cost of production, a few studies3 
have looked at the immunogenicity of reduced doses of Hib 
antigen in the vaccine. While these studies may differ with 
regard to which protein the Hib is conjugated to (tetanus 
toxoid protein (PRP-T) or mutant diphtheria toxin CRM197 
(HbOC)), there is growing evidence that reduced amount of 
antigen in the vaccine, e.g 2.5 µg or 5 µg, is as protective as the 
conventional 10 µg dose.4 With such evidence coming through 
it is clear that the future of Hib vaccines will lie with the 
reduced Hib antigen. 
Another development likely to ease the burden of 
programme managers is the shift from freeze-dried Hib 
vaccine (which has to be reconstituted before administration) 
to fully liquid Hib vaccine. As the world moves closer to liquid 
combination vaccines (mixing even up to 5 components, e.g 
D, T, P, HepB, and Hib), the administration of the Hib vaccine 
should with time be even more cost-effective for immunisation 
programmes in many countries.
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Retention of a vaginal ring pessary in a 
postmenopausal patient
To the Editor: There is probably still a place, albeit small, for 
the use of a vaginal ring pessary. The ring pessary is usually 
used in elderly patients with symptomatic genital prolapse, 
especially where the patient is medically unfit for surgery or 
does not want an operation. Usually the ring pessary is not 
associated with significant complications. This case report 
demonstrates one possible complication.
A 75-year-old woman, G8P8, had had all her babies by the 
natural route. She first visited the practice in December 1999, 
requesting that the ring pessary that had been inserted some 
years before be checked. On examination she was found to 
have significant genital prolapse; the ring was still in position 
and was removed with ease. A significant degree of atrophy 
was present. The cervix could not be identified but a small 
postmenopausal uterus was present. Because she was a 
diabetic, hypertensive, cardiac patient, and was comfortable 
with the ring, surgery was not offered. The ring was reinserted 
and she was advised to use vaginal oestrogen cream on a 
regular basis, and asked to report every 6 months. The smear 
revealed atrophic cytology, no malignancy.
The patient was followed up for 5 years, at 6-monthly 
intervals. She then stayed away for 18 months; when she was 
seen after this interval, the ring was found stuck in the vagina. 
It could not be removed. The top part of the ring was covered 
over by a bridge of epithelium extending between the anterior 
and posterior vaginal fornices, thus fixing the ring in the 
vagina. The patient was reluctant to have it removed surgically. 
Also, the ring had served her well for many years. The ring 
was therefore manoeuvred back into its usual position. She 
was again advised to use vaginal oestrogen cream on a regular 
basis. She was discharged and is being followed up.
Vaginal entrapment of foreign bodies has been reported in 
this Journal several times.1-3 The foreign bodies included among 
others a salt cellar,1 the plastic cap of a spray canister2 and an 
engagement ring,3 with a large diamond. The present case again 
demonstrates the apparent natural phenomenon of vaginal 
‘encapsulation’, ‘burial’ or engulfment of a foreign body if left 
in the vagina for long enough. In this case the degree of genital 
atrophy must have played a role in the pathology.
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